Mercado Global de Medicamentos Peptídeos e Anticoagulantes – Tendências da Indústria e Previsão para 2029

Análise e dimensão do mercado                              

A doença coronária e o enfarte do miocárdio (EM) são considerados um grande problema de saúde pública em todo o mundo. Nos Estados Unidos, o número de doentes com doença arterial coronária aumentou visivelmente. De acordo com a American Heart Association (AHA), cerca de uma em cada sete mortes nos Estados Unidos ocorreu em 2018. De acordo com o inquérito, os adultos com infeção cardíaca representam quase 7,9 milhões (3%) de pessoas. Como resultado, a procura pelo mercado de medicamentos peptídicos e anticoagulantes aumentou drasticamente.

A Data Bridge Market Research analisa que o mercado de medicamentos peptídicos e anticoagulantes foi avaliado em 1,53 mil milhões de dólares em 2021 e deverá atingir os 2,45 mil milhões de dólares até 2029, registando um CAGR de 6,10% durante o período de previsão de 2022 a 2029. Além dos insights de mercado, tais como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também análise especializada aprofundada, epidemiologia do doente, análise de pipeline, análise de preços e quadro regulamentar.

Âmbito do relatório e segmentação de mercado

Market Definition

Blood thinners are anticoagulants, which are chemical agents that inhibit blood coagulation and blood clotting time. Anticoagulants are a pharmacological class of drugs used to treat thrombotic diseases. Oral anticoagulants come in pill, tablet, and injectable dose forms. Herapins, low molecular weight heparins (LMWHs), warfarin, direct thrombin inhibitors and factor Xa inhibitors are the most common anticoagulants (DTIs). Heparin is an injectable anticoagulant commonly used in hospitals to prevent blood clotting. Subcutaneous injections of LMWHs are given twice a day to treat DVT. Peptides, also known as amide bonds, are long-chain amino acids bound together by peptide bonds. Peptides are a special class of medicinal substances that are molecularly made up of tiny molecules and proteins. The therapeutic characteristics of peptides are deployed to treat a variety of disorders.

Peptide and Anticoagulant Drugs Market Dynamics

Drivers

• Increasing cases of coronavirus infection globally

The rising coronavirus infection cases globally are anticipated to drive the peptide and anticoagulant drugs market's growth. According to new research, hypercoagulability in those infected by the coronavirus disease (COVID-19) pandemic could be one of the major causes of death globally. As a result, the rising number of instances is driving up demand for anticoagulant medications to treat thrombosis in critically unwell or hospitalized patients.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of peptide and anticoagulant drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Increasing prevalence of cardiovascular diseases

The increased prevalence of cardiovascular diseases will fuel industry growth. The rise in cardiovascular disorders is propelling the industry forward. Cardiovascular diseases are a major driver of market expansion. Cardiovascular disorders are the main cause of death worldwide, accounting for about 18.6 million deaths in 2019, as per the Heart Disease and Stroke Statistics Update Fact Sheet published in 2021. Each year, cardiovascular disorders cause more deaths than cancer and chronic lower respiratory disease (CLRD) combined. Additionally, increasing prevalence of chronic diseases in both the elderly and middle-aged populations is estimated to propel the market's growth rate.

Furthermore, surging geriatric population and rise in the number of infected patients globally will result in the expansion of peptide and anticoagulant drugs market. Along with this, the sedentary lifestyle of people such as rising addiction of smoking and extended sitting and favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Technological advancement

The industry is projected to benefit from technological advancements in the development of anticoagulant products. Advanced technologies such as microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and micro/nano electromechanical systems (MEMS/NEMS) have been used to develop highly accurate, robust, and cost-effective anticoagulant products, according to a study published in the Frontier in Biotehnology and Bioengineering in December 2019.

Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the peptide and anticoagulant drugs market growth.

Restraints/Challenges

• Side effects linked with anticoagulants

Anticoagulant side effects may stymie market growth over the projection period. Heparin-induced thrombocytopenia causes the immune system to produce antibodies against the body's own platelets, which increases the risk of bleeding. For illustration, the FDA gets roughly 450,000 adverse medication events per year, with 3.8 percent of those involving heparin, reducing market income. Warfarin can also cause chrondrodysplasia punctata, asplenia, and foetal malformations, among other things. The industry's value will be harmed by such side consequences. Despite the fact that important market leaders are attempting to develop novel products, side effects may reduce their acceptance rate.

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the market of peptide and anticoagulant drugs. Additionally, lack of awareness among people and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This peptide and anticoagulant drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the peptide and anticoagulant drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Peptide and anticoagulant drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Peptide and Anticoagulant Drugs Market

Due to the rapid speed of research, COVID-19 infection is predicted to significantly influence the peptide and anticoagulant drugs market. As per a study published in the American Journal of Cardiovascular Drugs in 2020, more than ten clinical trials are underway to assess the potential of anticoagulants in COVID-19 patients and research on parenteral administration strategies for parenteral these drugs is being conducted for use in critically ill COVID-19 patients. Furthermore, patients with COVID-19, both confirmed and suspected, should have access to follow-up care with low-dose anticoagulants, according to a World Health Organization Update published in January 2021. As a result, anticoagulant demand surged during COVID-19.

Recent Development

• In December 2020, Natco Pharma had announced the launch of an anticoagulant medication named Rivaroxaban (RPIGAT). Rivaroxaban is an anticoagulant drug that treats and prevents blood clots. In India, Bayer markets the drug as Xarelto.

Global Peptide and Anticoagulant Drugs Market Scope

The peptide and anticoagulant drugs market is segmented on the basis of type, indication, low molecular weight heparin type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Low Molecular Weight Heparin Type

• Heparin Sodium
• Enoxaparin Sodium
• Dalteparin Sodium
• Fondaparinux

Type

• Hormonal
• Antibiotic
• ACE Inhibitor
• Antifungal
• Others

Indication

• Diabetes
• Infectious Diseases
• Cancer
• Osteoporosis
• Cardiology
• Gynecology
• Others

Route of Administration

• Oral
• Injectable
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Peptide and Anticoagulant Drugs Market Regional Analysis/Insights

The peptide and anticoagulant drugs market is analysed and market size insights and trends are provided by country, type, indication, low molecular weight heparin type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the peptide and anticoagulant drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

A América do Norte domina o mercado de medicamentos peptídicos e anticoagulantes em termos de quota de mercado e receitas de mercado e continuará a florescer o seu domínio durante o período de previsão. Isto deve-se à crescente procura de tratamento específico de doenças e o aumento dos gastos com a saúde irá impulsionar ainda mais a taxa de crescimento do mercado nesta região. Além disso, a crescente presença dos principais intervenientes e o aumento da adoção de tecnologias mais recentes impulsionarão ainda mais a taxa de crescimento do mercado nesta região.

Prevê-se que a Ásia-Pacífico seja a região que mais cresce durante o período de previsão de 2022-2029 devido ao aumento do número de população geriátrica nesta região. Além disso, o desenvolvimento da infra-estrutura de saúde e o aumento das iniciativas governamentais impulsionarão ainda mais a taxa de crescimento do mercado nesta região.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Análise do cenário competitivo e da quota de mercado dos medicamentos peptídicos e anticoagulantes

O panorama competitivo do mercado de medicamentos peptídicos e anticoagulantes fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado dos peptídeos e anticoagulantes.

Alguns dos principais players que trabalham no mercado dos peptídeos e medicamentos anticoagulantes são:

• F. Hoffmann-La Roche Ltd. (Suíça)
• Mylan NV (EUA)
• Teva Pharmaceutical Industries Ltd. (Irlanda)
• Sanofi (França)
• (EUA)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suíça)
• Merck & Co., Inc.
• Allergan (Irlanda)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (EUA)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Fresenius Kabi AG (Alemanha)
• Eisai Co., Ltd. (Japão)
• Empresa Bristol-Myers Squibb (EUA)
• Bayer AG (Alemanha)
• DAIICHI SANKYO COMPANY, LIMITED (Japão)
• Boehringer Ingelheim International GmbH. (Alemanha)
• (Índia)
• Aspen Holdings (África do Sul)

SKU-53318